πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 2,828 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11780845

FGFR inhibitors and methods of use thereof

Relay Therapeutics, Inc. Β· Granted Tue Oct 10 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11780837

CXCR4 inhibitors and uses thereof

X4 Pharmaceuticals, Inc. Β· Granted Tue Oct 10 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11780821

Inhibitors of fibroblast activation protein

PRAXIS BIOTECH LLC Β· Granted Tue Oct 10 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11773393

Treatment of liver diseases with cell death inducing DFFA like effector B (CIDEB) inhibito

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Oct 03 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11767526

Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Sep 26 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11767334

Heteroaryl inhibitors of PDE4

Tetra Discovery Partners Β· Granted Tue Sep 26 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11759476

Methods of treating metabolic disorders and cardiovascular disease with Inhibin Subunit Be

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Sep 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11759461

Small molecule inhibitors of cancer stem cells and mesenchymal cancer types

THE UNIVERSTY OF TEXAS SYSTEM,BOARD OF REGENTS Β· Granted Tue Sep 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11759453

SHMT inhibitors

THE TRUSTEES OF PRINCETON UNIVERSITY Β· Granted Tue Sep 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11752138

Treating primary or idiopathic hyperoxaluria with small molecule inhibitors of lactate deh

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Sep 12 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11752195

Compositions and methods of use of synthetic peptides with Mycobacterium abscessus inhibit

ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY Β· Granted Tue Sep 12 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11753381

Inhibitors of receptor interacting protein kinase I for the treatment of disease

The Board of Regents of the University of Texas System Β· Granted Tue Sep 12 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11753366

Tetrahydro-1H-cyclopenta[cd]indene derivatives as hypoxia inducible factor-2(alpha) inhibi

NIKANG THERAPEUTICS, INC. Β· Granted Tue Sep 12 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11744831

Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infec

United States Government as represented by the Department of Veterans Affairs Β· Granted Tue Sep 05 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 31 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11739093

Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric

Revolution Medicines, Inc. Β· Granted Tue Aug 29 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 24 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11739086

Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same

Aclaris Therapeutics, Inc. Β· Granted Tue Aug 29 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 24 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11739074

Ras inhibitors

Revolution Medicines, Inc. Β· Granted Tue Aug 29 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 24 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11731986

Inhibitors of low molecular weight protein tyrosine phosphatase (LMPTP) and uses thereof

SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE Β· Granted Tue Aug 22 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 17 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11731968

Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preven

HEPAREGENIX GMBH Β· Granted Tue Aug 22 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 17 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11732005

Peptidomimetic proteasome inhibitors

Tri-Institutional Therapeutics Discovery Institute, Inc. Β· Granted Tue Aug 22 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 17 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11730720

ALK5 inhibitors

Theravance Biopharma R&D IP, LLC Β· Granted Tue Aug 22 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 17 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11725008

Ethanediamine-heterocycle derivatives as inhibitors of protein arginine methyltransferases

The Board of Regents of the University of Texas System Β· Granted Tue Aug 15 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 10 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11718616

JAK kinase inhibitor compounds for treatment of respiratory disease

Theravance Biopharma R&D IP, LLC Β· Granted Tue Aug 08 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 03 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11718618

Substituted pyrido[2,1-a]isoquinolines as VMAT2 inhibitors

Neurocrine Biosciences, Inc. Β· Granted Tue Aug 08 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 03 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted